# Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)

> **NCT00135005** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 59 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumors

## Interventions

- **DRUG:** AMN107, STI571

## Key facts

- **NCT ID:** NCT00135005
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2006-11
- **Final completion:** 2006-11
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2020-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00135005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00135005, "Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00135005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*